“Sun Pharma, India’s largest pharmaceutical company by revenue, reported second-quarter profits in 2024 above analysts’ estimates, driven by higher demand for its specialty drugs to treat rare diseases.
According to estimates by the London Stock Exchange Group (LSEG), the Mumbai-based company’s net profit for the quarter ending September 30 rose by 28% to 30.40 billion rupees (approximately $362 million), surpassing the average analyst estimate of 28.87 billion rupees.
The company’s specialty drug segment, which includes treatments for diseases like alopecia and psoriasis, saw a 19.2% increase in sales, reaching $286 million. This segment has accounted for over 18% of the company’s total sales in the 2024 fiscal year so far.”
